GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Roselia CicconeConcetta QuintarelliAntonio CameraMichele PezzellaSimona CarusoSimona ManniAlessio OttavianiMarika GuercioFrancesca Del BufaloMaria Cecilia QuadracciaDomenico OrlandoStefano Di CeccaMatilde SinibaldiMariasole AurigemmaLaura IaffaldanoAndrea SarcinelliMaria Luisa D'AmoreManuela CeccarelliFrancesca NazioVeronica MarabittiEzio GiordaMarco PezzulloCristiano De StefanisAndrea CaraiSabrina RossiRita AlaggioGiada Del BaldoMarco BecilliAngela MastronuzziBiagio De AngelisFranco LocatelliPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.